Kiora Pharmaceuticals (KPRX) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

KPRX Stock Forecast


Kiora Pharmaceuticals stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

KPRX Analyst Ratings


Buy

According to 1 Wall Street analysts, Kiora Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for KPRX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Feb 09, 2023Maxim Group-BuyUpgrade
Row per page
Go to

Kiora Pharmaceuticals's last stock rating was published by Maxim Group on Feb 09, 2023. The company Upgrade its KPRX rating from "null" to "Buy".

Kiora Pharmaceuticals Financial Forecast


Kiora Pharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24
Revenue--------
Avg Forecast$15.00K$14.00K$13.00K$12.50K$507.67K$10.50K$20.00K$16.00M
High Forecast$15.00K$14.00K$13.00K$12.50K$508.83K$10.75K$20.00K$16.00M
Low Forecast$15.00K$14.00K$13.00K$12.50K$506.50K$10.25K$20.00K$16.00M
# Analysts11123111
Surprise %--------

Kiora Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. KPRX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Kiora Pharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24
# Analysts11123111
EBITDA--------
Avg Forecast$3.00K$2.80K$2.60K$2.50K$101.53K$2.10K$4.00K$3.20M
High Forecast$3.00K$2.80K$2.60K$2.50K$101.77K$2.15K$4.00K$3.20M
Low Forecast$3.00K$2.80K$2.60K$2.50K$101.30K$2.05K$4.00K$3.20M
Surprise %--------

undefined analysts predict KPRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kiora Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Kiora Pharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24
# Analysts11123111
Net Income--------
Avg Forecast$-2.55M$-2.49M$-2.51M$-3.14M$-2.53M$-3.22M$-3.57M$10.43M
High Forecast$-2.55M$-2.49M$-2.51M$-3.14M$-2.53M$-3.22M$-3.57M$10.43M
Low Forecast$-2.55M$-2.49M$-2.51M$-3.14M$-2.53M$-3.22M$-3.57M$10.43M
Surprise %--------

Kiora Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KPRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Kiora Pharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24
# Analysts11123111
SG&A--------
Avg Forecast$1.17M$1.09M$1.02M$977.43K$39.70M$821.04K$1.56M$1.25B
High Forecast$1.17M$1.09M$1.02M$977.43K$39.79M$840.59K$1.56M$1.25B
Low Forecast$1.17M$1.09M$1.02M$977.43K$39.61M$801.49K$1.56M$1.25B
Surprise %--------

Kiora Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to KPRX last annual SG&A of $NaN (undefined).

Kiora Pharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24
# Analysts11123111
EPS--------
Avg Forecast$-0.60$-0.59$-0.59$-0.74$-0.60$-0.76$-0.86$2.48
High Forecast$-0.60$-0.59$-0.59$-0.74$-0.60$-0.76$-0.86$2.48
Low Forecast$-0.60$-0.59$-0.59$-0.74$-0.60$-0.76$-0.86$2.48
Surprise %--------

According to undefined Wall Street analysts, Kiora Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KPRX previous annual EPS of $NaN (undefined).

Kiora Pharmaceuticals Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
KPRXKiora Pharmaceuticals$3.22$120.003626.71%Buy
BWVOnconetix$0.18$4.002122.22%Buy
PALIPalisade Bio$2.39$1.50-37.24%Buy

KPRX Forecast FAQ


Is Kiora Pharmaceuticals a good buy?

Yes, according to 1 Wall Street analysts, Kiora Pharmaceuticals (KPRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of KPRX's total ratings.

What are Kiora Pharmaceuticals's analysts' financial forecasts?

Kiora Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $16.54M (high $16.54M, low $16.54M), average EBITDA is $3.31M (high $3.31M, low $3.31M), average net income is $1.11M (high $1.11M, low $1.11M), average SG&A $1.29B (high $1.29B, low $1.29B), and average EPS is $0.255 (high $0.255, low $0.255). KPRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $54.5K (high $54.5K, low $54.5K), average EBITDA is $10.9K (high $10.9K, low $10.9K), average net income is $-10.685M (high $-10.685M, low $-10.685M), average SG&A $4.26M (high $4.26M, low $4.26M), and average EPS is $-2.535 (high $-2.535, low $-2.535).